NCT01019356View on ClinicalTrials.gov

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions

Polycystic Ovary Syndrome

Interventions

DRUG

Rosiglitazone

4 mg twice daily for 8 weeks orally

DRUG

Acarbose

100 mg three times daily for 8 weeks orally

Trial Locations (1)

J1H 5N4

Université de Sherbrooke, Sherbrooke

All Listed Sponsors

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Jean-Patrice Baillargeon

OTHER

NCT01019356 - Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter